Multiple small molecule inhibitors have been developed as monotherapies to target chromatin regulators in AML, with varying degrees of efficacy, such as inhibitors of Menin, DOT1L, HDAC, EZH2, Lysine-specific histone demethylase 1 (LSD1), and BET proteins (Figure 3). This evidence concerns the gene DOT1L and acute myeloid leukemia.